Page last updated: 2024-12-09

2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-1-benzopyran-4-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

**2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-1-benzopyran-4-one** is the chemical name for **fisetin**, a natural flavonoid pigment found in various fruits, vegetables, and plants.

**Importance in Research:**

**1. Antioxidant Properties:**
- Fisetin is a potent antioxidant, meaning it can neutralize free radicals in the body, protecting cells from damage.
- This property has implications for research into age-related diseases, inflammation, and cancer prevention.

**2. Neuroprotective Effects:**
- Studies have shown that fisetin may protect neurons from damage and promote brain health.
- It has been investigated for its potential role in preventing Alzheimer's disease, Parkinson's disease, and stroke.

**3. Anti-inflammatory Activity:**
- Fisetin has demonstrated anti-inflammatory properties, inhibiting the production of inflammatory mediators.
- This makes it a promising candidate for research into conditions like arthritis, asthma, and inflammatory bowel disease.

**4. Anticancer Potential:**
- Fisetin has exhibited anticancer activity in laboratory and animal studies, suggesting it may inhibit tumor growth and promote apoptosis (programmed cell death) in cancer cells.

**5. Cardiovascular Health:**
- Fisetin may improve cardiovascular health by lowering blood pressure, reducing cholesterol levels, and improving blood vessel function.

**6. Other Potential Benefits:**
- Research is exploring the potential benefits of fisetin in other areas, such as:
- Improving cognitive function
- Protecting against age-related macular degeneration
- Promoting wound healing

**Research Focus Areas:**

- Understanding the mechanisms of action of fisetin's various beneficial effects.
- Developing safe and effective fisetin-based therapies for human diseases.
- Investigating the bioavailability and pharmacokinetics of fisetin in the body.

**Note:** While fisetin shows promise in research, further studies are needed to fully understand its therapeutic potential in humans.

Cross-References

ID SourceID
PubMed CID688798
CHEMBL ID222541
CHEBI ID125596
SCHEMBL ID35318

Synonyms (26)

Synonym
3440-24-2
3',4',7,8-tetrahydroxyflavone
CHEBI:125596
7,8,3',4'-tetrahydroxyflavone
CHEMBL222541 ,
7,8,3'',4''-tetrahydroxyflavone
2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-4h-chromen-4-one
bdbm50157547
2-(3,4-dihydroxyphenyl)-7,8-dihydroxychromen-4-one
ST059620
2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-chromen-4-one
FT-0614178
BRD-K58443469-001-01-0
SCHEMBL35318
AKOS024283046
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-
Q27216211
2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-1-benzopyran-4-one
mfcd00017435
DTXSID20350973
2-[3,4-bis(oxidanyl)phenyl]-7,8-bis(oxidanyl)chromen-4-one
SQH ,
PD183059
7,8,3 inverted exclamation marka,4 inverted exclamation marka-tetrahydroxyflavone
HY-N8600
CS-0148693
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
flavonesA member of the class of flavonoid with a 2-aryl-1-benzopyran-4-one (2-arylchromen-4-one) skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Telomerase reverse transcriptaseHomo sapiens (human)IC50 (µMol)0.32400.00062.69489.4000AID1433314; AID281989; AID704075; AID704076; AID704077
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)0.07000.03403.987110.0000AID1167963
Bromodomain-containing protein 4Homo sapiens (human)IC50 (µMol)0.20400.00040.40329.0500AID1867009
Cyclin-dependent kinase 2Homo sapiens (human)IC50 (µMol)500.00000.00041.044410.0000AID298693
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.74000.00030.71237.0700AID1433314
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)IC50 (µMol)0.74000.00202.123310.0000AID1433314
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (72)

Processvia Protein(s)Taxonomy
telomere maintenanceTelomerase reverse transcriptaseHomo sapiens (human)
RNA-templated transcriptionTelomerase reverse transcriptaseHomo sapiens (human)
RNA-templated DNA biosynthetic processTelomerase reverse transcriptaseHomo sapiens (human)
telomere maintenance via telomeraseTelomerase reverse transcriptaseHomo sapiens (human)
mitochondrion organizationTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of gene expressionTelomerase reverse transcriptaseHomo sapiens (human)
DNA strand elongationTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of Wnt signaling pathwayTelomerase reverse transcriptaseHomo sapiens (human)
siRNA processingTelomerase reverse transcriptaseHomo sapiens (human)
regulation of protein stabilityTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of protein bindingTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of hair cycleTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of neuron apoptotic processTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of angiogenesisTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of glucose importTelomerase reverse transcriptaseHomo sapiens (human)
response to cadmium ionTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityTelomerase reverse transcriptaseHomo sapiens (human)
establishment of protein localization to telomereTelomerase reverse transcriptaseHomo sapiens (human)
cellular response to hypoxiaTelomerase reverse transcriptaseHomo sapiens (human)
DNA biosynthetic processTelomerase reverse transcriptaseHomo sapiens (human)
replicative senescenceTelomerase reverse transcriptaseHomo sapiens (human)
siRNA transcriptionTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of miRNA transcriptionTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of transdifferentiationTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of protein localization to nucleolusTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of endothelial cell apoptotic processTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of stem cell proliferationTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of cellular senescenceTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandTelomerase reverse transcriptaseHomo sapiens (human)
regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
chromatin organizationBromodomain-containing protein 4Homo sapiens (human)
DNA damage responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
regulation of inflammatory responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 4Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
tRNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
transcription coactivator bindingTelomerase reverse transcriptaseHomo sapiens (human)
DNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
telomerase activityTelomerase reverse transcriptaseHomo sapiens (human)
telomerase RNA reverse transcriptase activityTelomerase reverse transcriptaseHomo sapiens (human)
RNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
RNA-directed DNA polymerase activityTelomerase reverse transcriptaseHomo sapiens (human)
RNA-dependent RNA polymerase activityTelomerase reverse transcriptaseHomo sapiens (human)
protein bindingTelomerase reverse transcriptaseHomo sapiens (human)
identical protein bindingTelomerase reverse transcriptaseHomo sapiens (human)
protein homodimerization activityTelomerase reverse transcriptaseHomo sapiens (human)
metal ion bindingTelomerase reverse transcriptaseHomo sapiens (human)
protein-folding chaperone bindingTelomerase reverse transcriptaseHomo sapiens (human)
telomerase RNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
template-free RNA nucleotidyltransferaseTelomerase reverse transcriptaseHomo sapiens (human)
telomeric DNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
transcription cis-regulatory region bindingBromodomain-containing protein 4Homo sapiens (human)
p53 bindingBromodomain-containing protein 4Homo sapiens (human)
chromatin bindingBromodomain-containing protein 4Homo sapiens (human)
transcription coregulator activityBromodomain-containing protein 4Homo sapiens (human)
transcription coactivator activityBromodomain-containing protein 4Homo sapiens (human)
protein bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityBromodomain-containing protein 4Homo sapiens (human)
enzyme bindingBromodomain-containing protein 4Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II C-terminal domain bindingBromodomain-containing protein 4Homo sapiens (human)
P-TEFb complex bindingBromodomain-containing protein 4Homo sapiens (human)
histone reader activityBromodomain-containing protein 4Homo sapiens (human)
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
PML bodyTelomerase reverse transcriptaseHomo sapiens (human)
chromosome, telomeric regionTelomerase reverse transcriptaseHomo sapiens (human)
nucleusTelomerase reverse transcriptaseHomo sapiens (human)
nucleoplasmTelomerase reverse transcriptaseHomo sapiens (human)
telomerase holoenzyme complexTelomerase reverse transcriptaseHomo sapiens (human)
nucleolusTelomerase reverse transcriptaseHomo sapiens (human)
cytosolTelomerase reverse transcriptaseHomo sapiens (human)
plasma membraneTelomerase reverse transcriptaseHomo sapiens (human)
nuclear speckTelomerase reverse transcriptaseHomo sapiens (human)
mitochondrial nucleoidTelomerase reverse transcriptaseHomo sapiens (human)
TERT-RMRP complexTelomerase reverse transcriptaseHomo sapiens (human)
telomerase catalytic core complexTelomerase reverse transcriptaseHomo sapiens (human)
nuclear telomere cap complexTelomerase reverse transcriptaseHomo sapiens (human)
RNA-directed RNA polymerase complexTelomerase reverse transcriptaseHomo sapiens (human)
condensed nuclear chromosomeBromodomain-containing protein 4Homo sapiens (human)
nucleusBromodomain-containing protein 4Homo sapiens (human)
nucleoplasmBromodomain-containing protein 4Homo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1867009Inhibition of human recombinant BRD4-BD2 expressed in Escherichia coli using C-Terminal-biotinylated histone H4 peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by microplate reader method2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development.
AID658255Cytotoxicity against human Huh7.5.1 cells by MTT assay2012European journal of medicinal chemistry, Jun, Volume: 52Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy.
AID704067Inhibition of tetrahymena telomerase using 3'-ACT TCG TAG AGC AGA TTG-5' as substrate at 1 uM incubated for 10 mins prior to extension reaction by telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID704077Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID1167963Inhibition of mushroom tyrosinase2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Structure-activity relationships of the thujaplicins for inhibition of human tyrosinase.
AID704055Inhibition of Thermus aquaticus DNA polymerase using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate after 15 mins by telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID704069Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate at 1 uM incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID704065Selectivity ratio of IC50 for tetrahymena telomerase to IC50 for telomerase in human HeLa cells by telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID704068Inhibition of tetrahymena telomerase using 3'-ACT TCG TAG AGC AGA TTG-5' as substrate incubated for 10 mins prior to extension reaction by telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID281992Inhibition of T3 RNA polymerase up to 2 uM2004Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
Catecholic flavonoids acting as telomerase inhibitors.
AID704076Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID704058Mixed type inhibition of tetrahymena telomerase using 3'-ACT TCG TAG AGC AGA TTG-5' as substrate assessed as ratio of IC50 at saturated substrate concentration to IC50 at Km by telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID502292Antioxidant activity assessed as DDPH radical scavenging activity2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Relationships between structures of hydroxyflavones and their antioxidative effects.
AID281990Inhibition of telomerase from A431 lysate at 1 uM by PCR-based cell-free TRAP assay2004Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
Catecholic flavonoids acting as telomerase inhibitors.
AID281989Inhibition of human telomerase from HEK293 cell extracts by Flash-Plate assay2004Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
Catecholic flavonoids acting as telomerase inhibitors.
AID704060Noncompetitive inhibition of telomerase in human HeLa cells using dNTP as substrate assessed as ratio of IC50 at saturated substrate concentration to IC50 at Km by telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID298693Inhibition of CDK22007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
3-Hydroxychromones as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
AID704064Mixed type inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate assessed as ratio of IC50 at saturated substrate concentration to IC50 at Km by telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID1867010Antiproliferative activity against human MV4-11 cells by CCK-8 assay2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development.
AID1433314Inhibition of telomerase activity (unknown origin) in cell free system using sulforhodamine labeled primer measured after 30 mins by telomerase repeat amplification protocol assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Targeting telomerase with radiolabeled inhibitors.
AID704070Binding affinity to Stenotrophomonas sp. TSG4 5'-(GGGATT)3GGGTT-3' DNA assessed as G-quadruplex stabilization at 2 uM by thermal melt analysis2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID281991Inhibition of telomerase in intact A431 cells at 1 uM2004Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
Catecholic flavonoids acting as telomerase inhibitors.
AID704075Inhibition of telomerase in human HEK293 cells by flashplate assay2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID704056Mixed type inhibition of tetrahymena telomerase using dNTP as substrate assessed as ratio of IC50 at saturated substrate concentration to IC50 at Km by telomeric repeat amplification protocol2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
A new strategy for detection and development of tractable telomerase inhibitors.
AID658253Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay2012European journal of medicinal chemistry, Jun, Volume: 52Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's5 (62.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.47 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]